Technology

Our Technologies

OST-tADC Tunable Drug Conjugates
OST-HER2 LM Vaccine

OST-tADCs (Tunable Drug Conjugates)

Ovarian Lung Pancreatic

tADCs can improve both efficacy and safety

Tunable drug conjugates (tADCs)

Improving efficacy

Smaller targeting moieties / ligands provide better tumor penetration
SiLinkers rapidly release payloads inside targeted cancer cells and in the acidic microenvironments of tumors
Conditionally Active Payloads (CAPs) only cross cell membranes and kill cancer cells under the same acidic conditions that our SiLinkrs cleave.
CAPs are trapped and concentrated in tumor cells

Improving safety

And, small ligands can direct rapid clearence of the tADC from the body
And, SiLinkers are relatively stable under normal physiological conditions that predominate throughout the body
And, CAPs do not readily enter normal cells under the physiological conditions prevalent throughout the body

Chemical manufacturing & control

tADCs are assembled chemically allowing precise control over the number of toxin payloads per tADC in payload cassettes and straightforward purification of final tADC moieties

How tADCs Work

1. Targeted receptor binding & internalization

tADCs, like ADCs, bind targeted receptors on cancer cells and are internalized

2. Cleavage and release of toxin payloads

The receptor - tADC Complex is trafficked inte the endosome / lysosome where an acidic pH causes rapid SiLinker cleavage and neutralizes CAPs so the can cross cell membranes

4. SiLinker / CAP combination enhances ‘bystander effect’

Large tumors have an acidic necrotic core allowing linker cleavage outside cells. CAPs permeate into targeted & non-targeted cancer cells increasing anti-tumor activity. If CAPs move outside the tumor, normal pH prevents them entering cells in normal tissues

3. CAP payloads are trapped inside targeted cancer cells

Cleaved CAPs permeate out of the endosome into the rest of the cancer cell where physiological pH traps the CAPs inside the cancer cell enhancing cell kill

OST-HER2 LM Vaccine

Osteosarcoma / Breast /Esophageal

OST-HER2 Mechanism of Action: T-Cells (Lymphocytes) Encircling and Destroying Osteosarcoma Micro-Metastasis in Canines

  1. Intravenous OST-HER2 vector rapidly cleared by immune system’s Antigen Presenting Cells (APCs)
  2. APCs are strongly activated, and generate potent HER2 specific T cells from within the patient
  3. T cells proliferate, travel through the blood, and are attracted to the Micro-Metastasis
  4. T cells then infiltrate and accumulate within the cancer cells - Tregs and MDSCs protecting the tumor are reduced
  5. T cells hunt down the cancer cells and attacks them directly, killing them by punching holes
  6. Cancer cells contents spill out and additional cancer targets are revealed
  7. New targets are taken up by the immune system
  8. T cells are generated against the new targets, repeating the cycle and extending the treatment effects

Dr. Robert Petit Describes The Importance of Trials in Humans Diagnosed with Osteosarcoma Through Translational use of OST-HER2 in CaninesAC

This treatment is important for osteosarcoma because of the potential it has to prevent or eliminate recurrences of the disease

Watch Video

Dr. Robert Petit Describes The Importance of Trials in Humans Diagnosed with Osteosarcoma Through Translational use of OST-HER2 in CaninesAC

This treatment is important for osteosarcoma because of the potential it has to prevent or eliminate recurrences of the disease

Watch Video
X

Ready to Help?

Volunteer today and help us achieve our goals
Join Today
We'd love to hear from you

Looking to join our mission?

Please let us know if you would be interested in joining our mission to identify and clinically prove new treatments for OsteoSarcoma. We are located in the Washington Metropolitan area near the NIH, FDA, researchers, capital and a thriving bio-science culture. Join us!

OS Therapies Logo White
© Copyright 2024 OS Therapies All rights reserved.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram